An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models

TIGIT (T-cell immunoglobulin and ITIM domain) has emerged as a promising target in cancer immunotherapy. It is an immune “checkpoint” inhibitor primarily expressed on activated T cells, NK cells and Tregs. Engagement of TIGIT to its ligands PVR and PVR-L2 leads to inhibitory signaling in T cells, pr...

Full description

Bibliographic Details
Main Authors: Xin Chen, Liu Xue, Xiao Ding, Jing Zhang, Lei Jiang, Sha Liu, Hongjia Hou, Bin Jiang, Liang Cheng, Qing Zhu, Lijie Zhang, Xiaosui Zhou, Jie Ma, Qi Liu, Yucheng Li, Zhiying Ren, Beibei Jiang, Xiaomin Song, Jing Song, Wei Jin, Min Wei, Zhirong Shen, Xuesong Liu, Lai Wang, Kang Li, Tong Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Immunology
Subjects:
TIGIT
antibody
Fc effector function
cancer immunotherapy
immune checkpoint
ociperlimab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.828319/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.828319/full

Similar Items